While no TPD molecule has yet entered clinical trials for neurodegenerative diseases, there have been several TPD methods directed against tau that demonstrate efficient degradation in various model systems (Table 1), which we aim to highlight here. This evidence concerns the gene MAPT and neurodegenerative disease.